Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.
OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a...
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility...
Preliminary Total Revenue for Q2 2022 was approximately $1.0 millionCash as of June 30, 2022 was approximately $16.6 millionFirst commercial customer...
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of...
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment for...
Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term...
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic...
Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12,...